A new modelling study in The Lancet Global Health examined the potential impact and cost-effectiveness of vaccination against Shigella burden, including stunting and the acute burden attributable to less severe diarrhea and moderate-to-severe diarrhea. Researchers used a simulation model to estimate Shigella burden and potential vaccination in children aged 5 years or younger from 102 low-income to middle-income countries from 2025 to 2044.
The findings showed that Shigella vaccination could avert 43 million (13−92) stunting cases and 590,000 (297,000–983,000) deaths over 20 years. The overall mean incremental cost-effectiveness ratio (ICER) was US$849 (95% uncertainty interval 423–1,575; median $790 [IQR 635–1,005]) per disability-adjusted life-year averted. Vaccination was most cost-effective in the WHO African region and in low-income countries.
The study suggests that Shigella vaccination would be a cost-effective intervention, with a substantial impact in specific countries and regions.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.